|
Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. |
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - AstraZeneca Canada |
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - AstraZeneca Canada |
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical |
Consulting or Advisory Role - Astellas Pharma; Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical |
Research Funding - Celgene (Inst); Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |